Estados financieros detallados de BioCryst Pharmaceuticals, Inc. (BCRX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
BioCryst Pharmaceuticals, Inc. registró ingresos de $874.8M en el último ejercicio fiscal, con un CAGR de 5 años del 117.9%.
Márgenes de los últimos 12 meses: margen bruto 23.5%, margen operativo -33.3%, margen neto -40.9%.
Al precio actual de $8.43, BCRX presenta beneficios negativos (P/E no significativo) y un ROE del 101.55%. La capitalización bursátil es de $2.1B.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Coste de Ventas | $2.7M | $1.7M | $471000 | $4.1M | $1.7M | $7.3M | $6.6M | $4.7M | $12.5M | $19.1M |
| Beneficio Bruto | $23.7M | $23.5M | $20.2M | $44.7M | $16.1M | $149.9M | $264.2M | $326.8M | $438.2M | $855.8M |
| I+D | $61.0M | $67.0M | $84.9M | $107.1M | $123.0M | $208.8M | $253.3M | $216.6M | $174.6M | $166.1M |
| Generales y Administrativos | $11.3M | $13.9M | $29.5M | $37.1M | $67.9M | $118.8M | $159.4M | $213.9M | $266.1M | $348.6M |
| Gastos Operativos | $72.3M | $80.9M | $114.4M | $144.2M | $190.9M | $327.6M | $412.7M | $430.5M | $440.8M | $514.8M |
| Beneficio Operativo | -$48.6M | -$57.4M | -$94.2M | -$99.5M | -$174.8M | -$177.7M | -$148.4M | -$103.7M | -$2.5M | $341.0M |
| EBITDA | -$48.2M | -$56.5M | -$90.4M | -$96.3M | -$167.6M | -$121.7M | -$143.9M | -$116.3M | $12.8M | $347.7M |
| Gastos por Intereses | $6.5M | $8.6M | $9.2M | $11.9M | $14.5M | $59.3M | $99.1M | $108.2M | $98.5M | $78.9M |
| Beneficio Antes de Impuestos | -$55.1M | -$65.8M | -$101.3M | -$108.9M | -$182.8M | -$181.8M | -$244.4M | -$226.2M | -$87.0M | $267.4M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | $2.3M | $2.7M | $310000 | $1.9M | $3.5M |
| Beneficio Neto | -$55.1M | -$65.8M | -$101.3M | -$108.9M | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| BPA | $-0.75 | $-0.78 | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | $1.26 |
| BPA Diluido | $-0.75 | $-0.78 | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | $1.21 |
| Acciones en Circulación (Diluidas) | $73.7M | $84.5M | $103.2M | $115.6M | $167.3M | $179.1M | $185.9M | $192.2M | $206.7M | $218.6M |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $22.1M | $50.3M | $26.7M | $114.2M | $272.1M | $504.4M | $304.8M | $110.6M | $104.9M | $89.7M |
| Inversiones a Corto | $32.5M | $64.1M | $77.7M | $22.1M | $28.2M | $3.2M | $119.5M | $278.3M | $216.1M | $185.0M |
| Cuentas por Cobrar | $8.8M | $6.1M | $4.3M | $22.1M | $8.6M | $29.4M | $50.6M | $57.0M | $79.1M | $106.8M |
| Inventario | $500000 | -$37.8M | $1.6M | 0 | $7.0M | $15.8M | $27.5M | $28.7M | $8.1M | $5.4M |
| Activos Corrientes | $67.0M | $125.4M | $114.4M | $164.3M | $323.8M | $566.1M | $516.5M | $496.0M | $422.0M | $404.3M |
| Inmovilizado Material | $9.9M | $9.5M | $9.1M | $7.3M | $7.1M | $15.2M | $8.6M | $20.9M | $19.8M | $19.0M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $89.8M | $178.3M | $146.8M | $175.3M | $334.7M | $588.2M | $550.0M | $517.0M | $490.4M | $514.2M |
| Cuentas por Pagar | $4.3M | $6.3M | $7.8M | $14.0M | $18.7M | $27.8M | $14.4M | $20.9M | $11.6M | $15.8M |
| Deuda a Corto | $28.2M | $35.1M | $33.7M | $38.6M | $30.0M | 0 | 0 | 0 | $35.4M | 0 |
| Pasivos Corrientes | $54.4M | $74.8M | $69.5M | $92.3M | $105.7M | $103.7M | $105.5M | $150.0M | $160.4M | $196.1M |
| Deuda a Largo | $22.8M | $16.8M | $25.4M | $41.3M | $244.5M | $585.5M | $733.3M | $811.3M | $795.9M | $427.2M |
| Pasivos Totales | $88.3M | $94.5M | $97.6M | $137.0M | $354.0M | $695.1M | $844.6M | $972.5M | $966.4M | $633.3M |
| Reservas | -$566.1M | -$631.8M | -$732.0M | -$840.6M | -$1.02B | -$1.21B | -$1.45B | -$1.68B | -$1.77B | -$1.51B |
| Patrimonio Neto | -$566.1M | -$631.8M | -$732.0M | $38.3M | -$19.3M | -$107.0M | -$294.6M | -$455.5M | -$475.9M | -$119.2M |
| Deuda Total | $53.7M | $54.7M | $61.8M | $84.7M | $279.5M | $593.2M | $741.5M | $825.1M | $841.4M | $438.9M |
| Deuda Neta | -$9.9M | -$101.0M | -$65.0M | -$51.6M | -$20.9M | $85.6M | $317.1M | $436.2M | $520.4M | $164.1M |
| Capital Circulante | $12.6M | $50.6M | $44.9M | $72.0M | $218.1M | $462.4M | $411.0M | $346.0M | $261.6M | $208.3M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$55.1M | -$65.8M | -$101.3M | -$108.9M | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| Amortizaciones | $483000 | $704000 | $770000 | $724000 | $748000 | $777000 | $1.4M | $1.7M | $1.2M | $1.4M |
| Compensación en Acciones | $8.5M | $12.6M | $9.4M | $17.7M | 0 | $34.6M | $44.7M | $55.6M | $65.4M | $85.1M |
| Cambio en Capital Circulante | -$7.6M | $9.3M | -$3.5M | -$872000 | $26.9M | $8.1M | -$58.9M | -$32.4M | -$87.3M | -$56.9M |
| Flujo de Caja Operativo | -$53.4M | -$41.1M | -$92.6M | -$89.6M | -$137.2M | -$142.2M | -$161.8M | -$95.1M | -$52.0M | $329.9M |
| Inversiones (CapEx) | -$5.3M | -$328000 | -$366000 | -$343000 | -$514000 | -$2.4M | -$1.4M | -$2.2M | -$1.1M | -$2.5M |
| Adquisiciones | $4000 | $12000 | $366000 | 0 | 0 | 0 | 0 | 0 | 0 | -$6.2M |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$58.7M | -$41.5M | -$92.9M | -$89.9M | -$137.7M | -$144.5M | -$163.2M | -$97.3M | -$53.1M | $327.4M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -4.4% | -18.0% | +136.5% | -63.5% | +782.4% | +72.3% | +22.4% | +36.0% | +94.1% | |
| Crecimiento Beneficio Neto (anual) | -19.3% | -53.9% | -7.6% | -67.9% | -0.7% | -34.3% | +8.3% | +60.8% | +396.9% | |
| Crecimiento BPA (anual) | -4.0% | -25.6% | +4.1% | -16.0% | +5.5% | -29.1% | +11.3% | +63.6% | +393.0% | |
| Cambio en Acciones (anual) | +14.6% | +22.2% | +12.0% | +44.7% | +7.1% | +3.8% | +3.4% | +7.5% | +5.7% | |
| Crecimiento FCF (anual) | +29.4% | -124.1% | +3.2% | -53.2% | -4.9% | -12.9% | +40.4% | +45.4% | +716.1% | |
| Margen Bruto | 89.8% | 93.2% | 97.7% | 91.6% | 90.6% | 95.4% | 97.6% | 98.6% | 97.2% | 97.8% |
| Margen Operativo | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Margen EBITDA | -182.8% | -224.4% | -437.5% | -197.2% | -940.7% | -77.5% | -53.1% | -35.1% | 2.8% | 39.7% |
| Margen Neto | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| Margen FCF | -222.8% | -164.7% | -450.0% | -184.1% | -773.2% | -92.0% | -60.3% | -29.4% | -11.8% | 37.4% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -1.2% | -1.1% | -0.1% | -2.2% | 1.3% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.80 | $-0.49 | $-0.90 | $-0.78 | $-0.82 | $-0.81 | $-0.88 | $-0.51 | $-0.26 | $1.50 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $73.7M | $84.5M | $103.2M | $115.6M | $167.3M | $179.1M | $185.9M | $192.2M | $206.7M | $209.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 101.55% |
| Rentabilidad sobre capital invertido | -88.96% |
| Rentabilidad sobre activos | -68.96% |
| Margen bruto | 23.52% |
| Margen operativo | -33.29% |
| Margen neto | -40.90% |
Salud financiera
| Deuda / Patrimonio | -0.90 |
| Ratio corriente | 2.32 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.83 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -8.44 | -6.29 | -8.23 | -3.67 | -6.83 | -13.45 | -8.63 | -5.08 | -17.49 | 6.19 |
| P/VC | -0.82 | -0.66 | -1.14 | 10.43 | -64.69 | -23.19 | -7.24 | -2.53 | -3.27 | -13.74 |
| P/V | 17.70 | 16.46 | 40.32 | 8.17 | 69.96 | 15.78 | 7.88 | 3.47 | 3.45 | 1.87 |
| Margen Bruto | 89.8% | 93.2% | 97.7% | 91.6% | 90.6% | 95.4% | 97.6% | 98.6% | 97.2% | 97.8% |
| Margen Operativo | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Margen Neto | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
Empresas relacionadas: ARDX · MAZE · NTLA · PHVS · STOK · SYRE · TRVI
Explorar sector: Healthcare · Biotechnology
Más secciones de BCRX: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones